The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2
PLOS Pathogens · 02.08.2024 · 20 (8) · e1012383
DOI: 10.1371/journal.ppat.1012383 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 02.08.2024. Verfasst von Jamie Guenthoer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, COVID-19, Antibodies, Viral. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, Howard Hughes Medical Institute.
Abstract (Originalsprache)
The SARS-CoV-2 virus responsible for the COVID-19 global pandemic has exhibited a striking capacity for viral evolution that drives continued evasion from vaccine and infection-induced immune responses. Mutations in the receptor binding domain of the S1 subunit of the spike glycoprotein have led to considerable escape from antibody responses, reducing the efficacy of vaccines and monoclonal antibody (mAb) therapies. Therefore, there is a need to interrogate more constrained regions of spike, such as the S2 subdomain. Here, we present a collection of S2 mAbs from two SARS-CoV-2 convalescent individuals that target multiple regions in S2, including regions outside of those commonly reported. One of the S2 mAbs, C20.119, which bound to a highly conserved epitope in the fusion peptide, was able to broadly neutralize across SARS-CoV-2 variants, SARS-CoV-1, and closely related zoonotic sarbecoviruses. The majority of the mAbs were non-neutralizing; however, many of them could mediate antibody-dependent cellular cytotoxicity (ADCC) at levels similar to the S1-targeting mAb S309 that was previously authorized for treatment of SARS-CoV-2 infections. Several of the mAbs with ADCC function also bound to spike trimers from other human coronaviruses (HCoVs), such as MERS-CoV and HCoV-HKU1. Our findings suggest S2 mAbs can target diverse epitopes in S2, including functional mAbs with HCoV and sarbecovirus breadth that likely target functionally constrained regions of spike. These mAbs could be developed for potential future pandemics, while also providing insight into ideal epitopes for eliciting a broad HCoV response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
- Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
- Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, United States of America.
- Howard Hughes Medical Institute, Seattle, Washington, United States of America.
ORCID-Profile: Julie Overbaugh
Förderung
- NIAID NIH HHS
- National Institutes of Health
- Howard Hughes Medical Institute
Zitieren
APA
Guenthoer, J., Garrett, M. E., Lilly, M., Depierreux, D. M., Ruiz, F., Chi, M., Stoddard, C. I., Chohan, V., Yaffe, Z. A., Sung, K., Ralph, D., Chu, H. Y., Matsen, F. A., & Overbaugh, J. (2024). The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2. PLOS Pathogens, 20(8), e1012383. https://doi.org/10.1371/journal.ppat.1012383
Vancouver
Guenthoer J, Garrett ME, Lilly M, Depierreux DM, Ruiz F, Chi M, et al. The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2. PLOS Pathogens. 2024;20(8):e1012383. doi:10.1371/journal.ppat.1012383
BibTeX
@article{Guenthoer2024,
author = {Guenthoer, Jamie and Garrett, Meghan E and Lilly, Michelle and Depierreux, Delphine M and Ruiz, Felicitas and Chi, Margaret and Stoddard, Caitlin I and Chohan, Vrasha and Yaffe, Zak A and Sung, Kevin and Ralph, Duncan and Chu, Helen Y and Matsen, Frederick A and Overbaugh, Julie},
title = {The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2},
journal = {PLOS Pathogens},
year = {2024},
volume = {20},
number = {8},
pages = {e1012383},
doi = {10.1371/journal.ppat.1012383}
}
EUVIMED